Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Azeez Farooki

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
JCO Oncology Practice|January 8, 2024
Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate CancerAaron P Mitchell, David Nemirovsky, Akriti Mishra Meza, et al.
The Prostate|October 17, 2023
Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancerAaron P Mitchell, Sonia Persaud, Paul Palyca, et al.
Leukemia Research|March 12, 2013
Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumorsEllin Berman, Monica Girotra, Catherine Cheng, et al.
Cardiovascular and Interventional Radiology|May 7, 2016
Ga-68 DOTATOC PET/CT-Guided Biopsy and Cryoablation with Autoradiography of Biopsy Specimen for Treatment of Tumor-Induced OsteomalaciaMajid Maybody, Ravinder K Grewal, John H Healey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathwayNaifa L Busaidy, Azeez Farooki, Afshin Dowlati, et al.
Journal of Bone Oncology|June 20, 2017
Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone scoreVeronica Mariotti, David B Page, Oksana Davydov, et al.
Journal of Cranio-Maxillo-Facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery|January 20, 2016
Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patientsAdepitan A Owosho, Ariel Blanchard, Lauren Levi, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2018
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin LymphomasBruce D Cheson, Susan O'Brien, Michael S Ewer, et al.
The Journal of Clinical Endocrinology and Metabolism|February 16, 2026
Exposure to GLP-1RA and risk of structural progression in differentiated thyroid cancerArmando Patrizio, Audrey Mauguen, James A Fagin, et al.
Breast Cancer Research : BCR|March 4, 2024
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancerJordi Rodón, David Demanse, Hope S Rugo, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
JCO Oncology Practice|January 8, 2024
Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate CancerAaron P Mitchell, David Nemirovsky, Akriti Mishra Meza, et al.
The Prostate|October 17, 2023
Physician knowledge, practice patterns, and barriers encountered regarding guideline-concordant use of bone modifying agents for prostate cancerAaron P Mitchell, Sonia Persaud, Paul Palyca, et al.
Leukemia Research|March 12, 2013
Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumorsEllin Berman, Monica Girotra, Catherine Cheng, et al.
Cardiovascular and Interventional Radiology|May 7, 2016
Ga-68 DOTATOC PET/CT-Guided Biopsy and Cryoablation with Autoradiography of Biopsy Specimen for Treatment of Tumor-Induced OsteomalaciaMajid Maybody, Ravinder K Grewal, John H Healey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2012
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathwayNaifa L Busaidy, Azeez Farooki, Afshin Dowlati, et al.
Journal of Bone Oncology|June 20, 2017
Assessing fracture risk in early stage breast cancer patients treated with aromatase-inhibitors: An enhanced screening approach incorporating trabecular bone scoreVeronica Mariotti, David B Page, Oksana Davydov, et al.
Journal of Cranio-Maxillo-Facial Surgery : Official Publication of the European Association for Cranio-Maxillo-Facial Surgery|January 20, 2016
Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patientsAdepitan A Owosho, Ariel Blanchard, Lauren Levi, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 26, 2018
Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin LymphomasBruce D Cheson, Susan O'Brien, Michael S Ewer, et al.
The Journal of Clinical Endocrinology and Metabolism|February 16, 2026
Exposure to GLP-1RA and risk of structural progression in differentiated thyroid cancerArmando Patrizio, Audrey Mauguen, James A Fagin, et al.
Breast Cancer Research : BCR|March 4, 2024
A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancerJordi Rodón, David Demanse, Hope S Rugo, et al.
Pageof 5